A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy.
Rosenthal A, Dueck AC, Ansell S, Gano K, Conley C, Nowakowski GS, Camoriano J, Leis JF, Mikhael JR, Keith Stewart A, Inwards D, Dingli D, Kumar S, Noel P, Gertz M, Porrata L, Russell S, Colgan J, Fonseca R, Habermann TM, Kapoor P, Buadi F, Leung N, Tiedemann R, Witzig TE, Reeder C.
Rosenthal A, et al. Among authors: gano k.
Am J Hematol. 2017 May;92(5):467-472. doi: 10.1002/ajh.24693. Epub 2017 Mar 22.
Am J Hematol. 2017.
PMID: 28230270
Free article.
Clinical Trial.